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Abstract
Background: Probiotics incorporated into dairy products have been shown to reduce total (TC) and LDL cholesterolemia
(LDL-C) in subjects with moderate hypercholesterolemia. More specifically, probiotics with high biliary salt hydrolase
activity, e.g. Bifidobacterium longum BB536, may decrease TC and LDL-C by lowering intestinal cholesterol reabsorption
and, combined with other nutraceuticals, may be useful to manage hypercholesterolemia in subjects with low
cardiovascular (CV) risk. This study was conducted to evaluate the efficacy and safety of a nutraceutical combination
containing Bifidobacterium longum BB536, red yeast rice (RYR) extract (10mg/day monacolin K), niacin, coenzyme Q10
(Lactoflorene Colesterolo®). The end-points were changes of lipid CV risk markers (LDL-C, TC, non-HDL-cholesterol (HDL-C),
triglycerides (TG), apolipoprotein B (ApoB), HDL-C, apolipoprotein AI (ApoAI), lipoprotein(a) (Lp(a), proprotein convertase
subtilisin/kexin type 9 (PCSK9)), and of markers of cholesterol synthesis/absorption.
Methods: A 12-week randomized, parallel, double-blind, placebo-controlled study. Thirty-three subjects (18–70 years) in
primary CV prevention and low CV risk (SCORE: 0–1% in 24 and 2–4% in 9 subjects; LDL-C: 130–200mg/dL) were
randomly allocated to either nutraceutical (N = 16) or placebo (N = 17).
Results: Twelve-week treatment with the nutraceutical combination, compared to placebo, significantly reduced TC
(− 16.7%), LDL-C (− 25.7%), non-HDL-C (− 24%) (all p < 0.0001), apoB (− 17%, p = 0.003). TG, HDL-C, apoAI, Lp(a), PCSK9
were unchanged. Lathosterol:TC ratio was significantly reduced by the nutraceutical combination, while campesterol:TC
ratio and sitosterol:TC ratio did not change, suggesting reduction of synthesis without increased absorption of cholesterol.
No adverse effects and a 97% compliance were observed.
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Conclusions: A 12-week treatment with a nutraceutical combination containing the probiotic Bifidobacterium longum
BB536 and RYR extract significantly improved the atherogenic lipid profile and was well tolerated by low CV risk subjects.
Trial registration: NCT02689934.
Keywords: Cardiovascular risk, Probiotic, Nutraceutical, Hypercholesterolemia, LDL-cholesterol, Non-HDL cholesterol,
Monacolin K
Background
Atherosclerosis-related cardiovascular (CV) diseases are
associated with greater disability, morbidity for concomi-
tant severe conditions and mortality [1]. In addition to
some subjects with severe hypercholesterolemia, mostly
related to genetic conditions [2], the majority of subjects
with low or medium CV risk actually show moderate
cholesterol elevation, together with moderate rise of re-
lated biomarkers [1]. This CV risk is often underdiag-
nosed and undertreated, thus representing a significant
burden for the individual, especially in combination with
unhealthy lifestyle habits [3]. In this field, statins are an
established and widely used therapeutic option and their
use has led to relevant improvements in the outcome of
CV diseases [4]. However, statins are also well-known to
be associated with important side-effects, such as muscle
symptoms of different entity [5] and, to a lower extent, de
novo diabetes mellitus development [6] indicating the need
for additional drug and nutraceutical treatment options.
In all these conditions, nutraceutical approach may be
a reasonable option, since in several instances a
moderate-intensity (multi)treatment may offer relevant
advantages over the no-treatment option or the presence
of inadequate adherence to a drug therapy, due for
example to adverse effects [7] or even as an add-on to
low dose statins in secondary prevention patients
intolerant to high dose statin [8]. Several nutraceutical
compounds have been evaluated both alone and in com-
bination in the context of moderate dyslipidemia [9, 10].
Among these, the most widely tested and used are
extracts of red yeast rice (RYR), berberine, phytosterols,
and stanols [11]. Interestingly, comparative studies be-
tween RYR and statins observed a smaller incidence of
muscular side effects with the former treatment [12].
Recent evidence indicates that alterations of gut micro-
biota may be involved in the pathogenesis of systemic dis-
eases related to CV risk, including hypercholesterolemia
[13], suggesting that the use of selected probiotics with
specific biological activities may be proposed for these
systemic conditions. Indeed, available data suggest that
the intake of selected probiotics, incorporated into a food
matrix like yogurt or fermented milk, may lead to a
significant reduction of total cholesterol (TC) (up to −
5.4%) and low-density lipoprotein-cholesterol (LDL-C)
(up to − 16%) [14–16]. More specifically, probiotic strains
showing high biliary salt hydrolase (BSH) activity [17, 18],
such as Bifidobacterium longum BB536, may contribute to
lower circulating TC and LDL-C by reducing intestinal
cholesterol reabsorption [19]. As such food matrices may
not be very practical for a long-term use, the incorpor-
ation of these probiotics into pharmaceutical forms, also
in association with other nutraceuticals, may result in
better adherence and efficacy for the management of low
CV risk subjects.
The main objective of the present study was the evalu-
ation of the efficacy and safety of a nutraceutical
combination containing Bifidobacterium longum BB536,
RYR extract, niacin and coenzyme Q10, on the improve-
ment of LDL-C level as the primary end-point, as well
as of a set of clinical and experimental markers of CV
risk (secondary end-points).
Methods
Study design and population
This was a randomized, double-blind, placebo-controlled,
parallel-group trial (RCT) (NCT02689934). It involved 33
subjects in primary CV prevention, with both low CV risk
and LDL-C in the 130–200mg/dL range. The study was
performed at the Centro Dislipidemie (ASST Grande
Ospedale Metropolitano Niguarda, Milan, Italy) in the
period from November 2015 to February 2017, in accord-
ance with the guidelines of the Declaration of Helsinki.
The study was approved by the Ethics Committee of
ASST Grande Ospedale Metropolitano Niguarda. A writ-
ten informed consent was obtained from each subject.
Sixteen males and 17 females, median aged 57 years (Q1
= 48 and Q3 = 63 years), with low total CVD risk (0–1% in
24/33 subjects (73%) and 2–4% in 9/33 subjects (27%)), as
assessed by the SCORE Risk Charts (http://www.hearts-
core.org/en_GB/) and LDL-C levels of 180 (170, 196) mg/
dL (median (Q1, Q3)) were recruited for the study (Fig. 1;
CONSORT flow diagram). After a run-in period of 4
weeks, patients were randomly assigned to receive, for 12
weeks, either the nutraceutical combination - Lactoflorene
Colesterolo® (1 sachet/d; granules for oral suspension) -
containing 1 bn UFC Bifidobacterium longum BB536,
RYR extract (10mg monacolin K), 16mg niacin, 20mg
coenzyme Q10; n = 16) or placebo (1 sachet/d; this latter
was identical in taste and appearance to the nutraceutical
combination sachet; n = 17) (Fig. 1). Both placebo and
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active treatment were packaged into a proprietary
2-compartment sachet (DUOCAM®), in order to preserve
probiotic integrity. This intervention was followed by a
final 4-week follow-up period.
The randomization table was obtained by computer-
generated random numbers. Inclusion criteria were: sub-
jects in primary prevention for CV disease, aged 18–70
years, LDL-C: 130–200 mg/dL, non-smokers. Exclusion
criteria were: pregnancy, current or previous smoking,
presence of diabetes mellitus, chronic liver disease, renal
disease, or severe renal impairment treated with antidia-
betic medications or insulin; untreated arterial hyperten-
sion; obesity (body mass index - BMI- ≥ 30 kg/m2; BMI
is calculated as weight divided by height squared); any
pharmacological treatments known to interfere with the
study treatment; and patients enrolled in another re-
search study in the past 90 days. To estimate the compli-
ance, the study subjects were asked to bring back all the
sachets left after the first and the second 45-day period.
Clinical procedures
At study entry, 5 of 30 patients were on standard antihy-
pertensive treatment, maintained for the entire duration
of the study (Additional file 1: Table S1). At the screen-
ing visit, subjects were instructed to follow a normocalo-
ric/low-saturated fat diet (Additional file 1: Table S2)
and the adherence to this dietary scheme was assessed
by phone calls every 2 weeks by the dietitian (RB). Clin-
ical and biochemical evaluations were performed at the
beginning and at the end of each treatment period. At
all visits, patients underwent a fasting venous blood
sampling and a full clinical examination, including the
determination of height, body weight, waist circumfer-
ence (by means of a non-stretchable tape at the umbil-
ical level (standing position), heart rate, and arterial
blood pressure. Bioelectric impedance analysis (BIA;
ViScan device (Tanita Inc., Tokio, Japan)) was used to
assess % abdominal fat mass (BIA (%)) and % visceral fat
rating (VFR (%)), according to previously reported
procedures (22). All visits were performed by the same
investigator (PM), and all ViScan analyses were con-
ducted by the same operator (RB). Plasma samples were
immediately separated by centrifugation, and aliquots
immediately stored at − 20 °C for subsequent assays.
Primary endpoint was change in LDL-C by study arms.
Secondary end points were changes in TC and other CV
biomarkers (non-HDL-C, triglycerides (TG), HDL-C,
apolipoprotein (apo)AI, apoB, lipoprotein(a) (Lp(a)), pro-
protein convertase subtilisin/kexin type 9 (PCSK9)).
Data retrieval, analysis, and manuscript preparation were
solely the responsibility of the authors.
Biochemical and immunometric assays
In each blood sample, TC, TG, HDL-C, apoAI, apoB,
Lp(a), fasting plasma glucose (FPG), uric acid, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
gamma-glutamyltranspeptidase (GGT), and creatine phos-
phokinase (CPK) isoenzymes were measured according to
Fig. 1 CONSORT statement flow diagram
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standard automated clinical procedure. LDL-C was calcu-
lated according to the Friedewald formula. Non-HDL-C
was calculated as TC minus HDL-C. Commercial
enzyme-linked immunosorbent assay (ELISA) kits were
used according to manufacturer’s specifications and previ-
ously published protocols to quantify PCSK9 [20],
fibroblast growth factor (FGF) 19 and FGF21, C-reactive
protein (all from R&D System, MN). In addition, oxi-
dized LDL (oxLDL), and insulin were also measured
(Mercodia, Sweden). The homeostasis model assess-
ment of insulin resistance (HOMA-IR) index was
calculated as follows: HOMA-IR = [fasting glucose
(mg/dL) * insulin (mUI/L)/405].
Determination of serum levels of lathosterol and plant
sterols
Deuterated lathosterol (0.5 μg) and 5α-cholestane
(0.5 μg) were added to 0.1 mL serum samples as internal
standards for the measurement of lathosterol and dietary
sterols (campesterol and sitosterol), respectively. After
alkaline hydrolysis with 1 mL 1 N NaOH in 90% ethanol
at 60 °C for 90 min under nitrogen, samples were
extracted with petroleum ether, transformed into tri-
methylsilyl (TMS) derivatives and analysed as described
previously [21].
Gas chromatography-mass spectrometry analysis
Analysis of sterols was carried out under previously de-
scribed conditions (23) monitoring ions at m/z 372 for
detection of cholestane, m/z 255 and 259 for lathosterol
and deuterated lathosterol, and m/z 382 and 396 for
campesterol and sitosterol, respectively. Lathosterol,
campesterol and sitosterol values were normalized by
total cholesterol levels. Calibration curves were prepared
spiking serum with fixed amounts of each internal
standard and increasing amounts of the above-men-
tioned sterols and were treated and analysed as the sam-
ples. Concentrations were calculated on the basis of the
slope of the standard curve and on the peak area ratio
(sterol/internal standard) found in the sample.
Sample size calculation
A group sample size of 16 per arm achieves 80%
power to detect a difference of 20 mg/mL in absolute
changes (12 weeks-0 week) in LDL-C levels (mg/mL),
between the null hypothesis that in both arms the
means of change in LDL-C are 10 mg/mL and the
alternative hypothesis that the mean of change in
LDL-C in the treatment arms is − 10 mg/mL [22].
The estimated group standard deviations were 25 mg/
mL per arm, with a significance level of 5% using a
two-sided two-sample t-test.
Statistical analysis
Results are presented as median and interquartile ranges
(Q1 and Q3) for all parameters. Differences in median
values between treatment arms at baseline were assessed
by Wilcoxon-rank sum test. The difference by treatment
arms of absolute changes and percentage changes of
biomarkers from baseline [12 weeks treatment - baseline
(0 week)] were expressed as median and interquartile
ranges. Differences in change by arms were evaluated by
ANCOVA models adjusted for baseline values and
uncontrolled confounding factors. Percentage changes
were assessed considering 20% as cut-off point of reduc-
tion [22]. Chi-square test and multivariate logistic re-
gression models were applied to evaluate the difference
between arms in frequencies of subjects with a 20%
reduction. Values of TC, HDL-C, LDL-C and TG were
analyzed by repeated-measure ANCOVA models. Mixed
effects models are adjusted for baseline value and
include as fixed effects: time, treatment arms and
age. Residual plots assessed the validity of the as-
sumptions of the models. Least square means are
obtained from the full model, adjusted for baseline
values, and are presented by time and treatment
arms. All tests are 2-sided, and P values 0.05 are
considered statistically significant. Statistical analysis
was performed by using the SAS Software version 9.3
(SAS, NC).
Results
Study population
All patients were in primary CV prevention and free
from liver/kidney disorders potentially affecting the
response to treatment and were not on any drug affect-
ing lipid/lipoproteins or glycaemic profile, including
thiazolidinediones or corticosteroids. The baseline clin-
ical and biochemical data indicate that the study subjects
showed low CV risk, with 73% of subjects with a SCORE
risk of 0–1%. Median TC was 271 (247, 288) mg/dL and
LDL-C was 180 (170, 196) mg/dL (median (Q1, Q3))
(Table 1). TG, HDL-C, body weight and BMI, waist
circumference and blood pressure were within the refer-
ence range [23, 24]. Primary and secondary end points
and any other clinical parameter at baseline did not
differ between the nutraceutical combination group and
the placebo group (Table 1).
Effect of nutraceutical treatment on biomarkers of CV risk
After 12 weeks, in the nutraceutical combination group,
compared to placebo, we observed significant changes of
the main atherogenic lipid parameters. LDL-C was
reduced by 45 mg/dL (p < 0.0001), corresponding to a −
25.7% reduction, TC decreased by 45 mg/dL (p < 0.0001),
a − 16.7%, apoB by 27mg/dL (p = 0.003), corresponding
to a − 17% decrease, and non-HDL-C by 45 mg/dL (p <
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0.0001), a − 24% decrease (Table 2). Similar changes were
already achieved after 6 weeks of treatment and
returned to baseline values after withdrawing the
nutraceutical treatment for 4 weeks (data not shown).
At the end of the treatment period, circulating oxLDL
levels were slightly but significantly reduced by the
nutraceutical combination. ApoAI, HDL-C, TG, Lp(a),
PCSK9 plasma levels were unchanged in both treat-
ment groups (Table 2). In the placebo group, no sig-
nificant variations in the circulating biochemical
parameters were found. Body weight, BMI, waist
circumference, systolic and diastolic blood pressure
and heart rate were not affected in any of the two
arms (Table 2).
Effects of nutraceutical treatment on cholesterol
metabolism
In order to assess whether the nutraceutical-induced
reduction of LDL-C and TC was due to changes in chol-
esterol synthesis and/or intestinal absorption, the
supposed mechanisms of action of RYR extract and Bifi-
dobacterium longum BB536, respectively. The circulating
levels of lathosterol, marker of cholesterol synthesis, and
of the dietary plant sterols beta-sitosterol and campes-
terol, markers of intestinal cholesterol absorption, were
thus measured. In the nutraceutical combination group,
compared to the placebo group, lathosterol:TC was
significantly reduced by − 24% (p = 0.0206), whereas
campesterol:TC and beta-sitosterol:TC were unchanged
(Table 3).
Safety, tolerability and compliance
Treatment with Lactoflorene Colesterolo® was well toler-
ated by all participants, who did not report any signifi-
cant side effects, including gastrointestinal tract or
neuromuscular symptoms. No changes in liver and kid-
ney function were observed. Moreover, we observed no
changes of FPG, insulin, HOMA-IR, FGF19 and FGF21
in both treatment groups (Table 2). The study subjects
showed a high (97%) compliance to both treatments.
Discussion
This double-blind RCT conducted in subjects with low
CV risk was aimed at exploring the efficacy and safety of
a novel nutraceutical association, combining the Bifido-
bacterium longum BB536, a probiotic with high BSH
activity (18), with a RYR extract, niacin and coenzyme
Q10 (Lactoflorene Colesterolo®). This nutraceutical
combination is well accepted, safe and effective in terms
of significant improvement of the atherogenic lipid pro-
file. The primary endpoint was met with a − 25.7% drop
in LDL-C; significant reductions were also found for TC
(− 16.7%), ApoB (− 17%) and non-HDL-C (− 24%). Since
a similar reduction of the lipid atherogenic markers was
already achieved after 6 weeks of treatment, this could
be a practical timeframe for assessing the individual
response in the clinics. The LDL-C goal recommended
by the EAS guidelines (LDL-C < 115mg/dL) [25] was
reached by 4/16 subjects, whereas in 7/16 participants
LDL-C was lower than 130 mg/dL, after nutraceutical
treatment, although an expected variability due to indi-
vidual responsiveness has been observed. The efficacy of
this nutraceutical combination in terms of improvement
of clinical lipid markers is comparable or even better
than that of several other widely used nutraceuticals,
evaluated by RCT studies [26–28].
The intake of selected probiotics incorporated into
milk or milk derivatives, as mentioned before, has been
found to improve the lipid profile of moderately
Table 1 Main baseline clinical and biochemical characteristics
of the study population
Baseline values Difference between arms
at baseline (P-value)
Age (years) 57 (48, 63) 0.01
Weight (kg) 65 (62, 78) 0.43
BMI (kg/m2) 24 (21, 27) 0.89
WC (cm) 88 (84, 94) 0.91
BIA (%) 31 (27, 40) 0.99
VFR (%) 11 (8, 12) 0.91
SBP (mmHg) 120 (120, 130) 0.54
DBP (mmHg) 80 (80, 80) 0.88
HR (bpm) 64 (60, 68) 0.24
TC (mg/mL) 271 (247, 288) 0.51
LDL-C (mg/mL) 180 (170, 196) 0.29
HDL-C (mg/mL) 60 (43, 77) 0.51
Non-HDL-C (mg/mL) 210 (193, 228) 0.24
TG (mg/mL) 115 (94, 150) 0.79
apoAI (mg/dL) 118 (95, 133) 0.28
apoB (mg/dL) 146 (134, 155) 0.07
oxLDL (U/L) 76.6 (69.7, 86.7) 0.08
Lp(a) (mg/dL) 6 (4, 12) 0.32
PCSK9 (ng/dL) 341 (285, 403) 0.81
FPG (mg/dL) 95 (89, 98) 0.97
Insulin (mUI/L) 3.38 (2.46, 4.92) 0.64
HOMA-IR 0.75 (0.57, 1.15) 0.72
FGF19 (pg/mL) 227 (173, 337) 0.87
FGF21 (pg/mL) 179 (119, 229) 0.37
Statistically significant P-values are indicated in bold
BMI body mass index, WC waist circumference, BIA bioelectrical impedance
analysis, VFR visceral fat rating, SBP Systolic blood pressure, DBP diastolic
blood pressure, HR heart rate, TC total cholesterol, LDL-C low-density
lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG
triglycerides, apoA-I apolipoprotein A-I, apoB apolipoprotein B, oxLDL oxidize
LDL, Lp(a) lipoprotein (a), PCSK9 proprotein convertase subtilisin/kexin type 9,
FPG fasting plasma glucose, sICAM-1 soluble intercellular adhesion molecular 1,
HOMA-IR Homeostatic Model Assessment of Insulin Resistance, FGF fibroblast
growth factor
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hypercholesterolemic subjects, with a significant (− 5/
18%) reduction of TC and LDL-C [15, 19], indicating
that this approach is relevant and needs to be further
pursued. In these studies, however, the amount of food
containing the probiotics was quite high (300–350 g or
mL of fermented milk or yogurt per day), making such
approach less practical for long-term treatments. On the
other hand, we show here that is reasonably simpler, safe
and even more effective, for a long-term treatment, to
propose a nutraceutical combination containing a pro-
biotic in a specific pharmaceutical form (granules for
oral suspension), packaged into a 2-compartment sachet
to preserve probiotic integrity. Interestingly, the extent
of LDL-C modifications with this nutraceutical combin-
ation is similar to the average reduction observed in
some of the earlier statin clinical trials, reported in the
Table 2 Summary of primary and secondary end points
Placebo Nutraceutical Difference of changes
between arms
Baseline 12 weeks Baseline 12 weeks P-value
Weight (kg) 65 (64, 79) 66 (63, 80) 63 (59, 75) 64 (58, 74) 0.57
BMI (kg/m2) 24 (21, 27) 24 (21, 27) 24 (22, 27) 24 (22, 27) 0.72
WC (cm) 88 (84, 94) 87 (82, 91) 86 (83, 94) 91 (82, 96) 0.74
BIA (%) 31 (26, 41) 31 (27, 40) 32 (27, 37) 30 (26, 38) 0.12
VFR (%) 10 (7, 12) 11 (8, 13) 11 (8, 12) 11 (8, 12) 0.83
SBP (mmHg) 125 (110, 130) 120 (110, 128) 120 (120, 130) 120 (115, 130) 0.95
DBP (mmHg) 80 (80, 80) 80 (70, 80) 80 (80, 80) 80 (80, 83) 0.46
HR (bpm) 65 (64, 68) 64 (60, 67) 64 (60, 68) 65 (62, 71) 0.23
TC (mg/mL) 271 (256, 289) 267 (259, 293) 271 (239, 285) 208 (201, 263) <.0001
LDL-C (mg/mL) 189 (174, 198) 183 (171, 202) 177 (167, 193) 136.5 (118, 151.5) <.0001
HDL-C (mg/mL) 56 (48, 65) 58.5 (50, 68) 71 (43, 81) 71 (48, 88) 0.97
Non-HDL-C (mg/mL) 215 (198, 232) 217 (199, 232) 206 (189, 214) 198 (182, 208) <.0001
TG (mg/mL) 113 (94, 127) 112 (99, 148) 127 (93, 156) 106 (80, 124) 0.66
apoAI (mg/dL) 113.5 (97.5, 126.5) 110 (94.5, 120) 128 (93, 139) 128 (100, 151) 0.24
apoB (mg/dL) 143.5 (134, 148) 135 (133, 151) 155 (137, 158) 118 (112, 131) 0.003
oxLDL (U/L) 71.2 (66.7, 84.0) 76.4 (71.1, 99.5) 78.3 (74.6, 129.0) 81.0 (64.5, 114.1) 0.014
Lp(a) (mg/dL) 4.5 (2, 15.5) 4 (2, 17.5) 7 (4.5, 12) 9 (4, 14.5) 0.20
PCSK9 (ng/dL) 341 (294, 375) 324 (259, 360) 341 (294, 375) 346 (302, 366) 0.38
FPG (mg/dL) 95 (90, 97) 93 (87, 101) 93 (89, 101) 95 (92, 103) 0.20
Insulin (mUI/L) 3.23 (2.64, 5.24) 3.04 (2.31, 6.51) 3.38 (2.24, 4.92) 3.01 (2.38, 5.12) 0.78
HOMA-IR 0.73 (0.59, 1.23) 0.69 (0.51, 1.64) 0.77 (0.52, 1.15) 0.77 (0.49, 1.24) 0.92
FGF19 (pg/mL) 233 (166, 337) 261 (164, 305) 218 (177, 299) 221 (183, 374) 0.98
FGF21 (pg/mL) 185 (72, 227) 148 (77, 263) 179 (158, 364) 161 (66, 309) 0.11
Data are shown as median (1st quartile, 3rd quartile)
Statistically significant P-values are indicated in bold
BMI body mass index, WC waist circumference, BIA bioelectrical impedance analysis, VFR visceral fat rating, SBP Systolic blood pressure, DBP diastolic blood
pressure, HR heart rate, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides, apoA-I
apolipoprotein A-I, apoB apolipoprotein B, oxLDL oxidize LDL, Lp(a) lipoprotein (a), PCSK9 proprotein convertase subtilisin/kexin type 9, FPG fasting plasma glucose,
sICAM-1 soluble intercellular adhesion molecular 1, HOMA-IR Homeostatic Model Assessment of Insulin Resistance, FGF fibroblast growth factor
Table 3 Determination of serum levels of lathosterol and plant sterols
Placebo Nutraceutical Difference of changes
between arms
Baseline 12 weeks Baseline 12 weeks P-value
Lathosterol:TC 0.78 (0.62, 0.84) 0.72 (0.6, 0.82) 0.71 (0.52, 1.01) 0.57 (0.41, 0.8) 0.0206
Campesterol:TC 1.45 (0.78, 1.76) 1.38 (0.94, 2.12) 1.18 (0.84, 1.79) 1.41 (1.04, 1.92) 0.37
Beta-sitosterol:TC 1.80 (1.00, 2.56) 1.67 (1.28, 2.14) 1.62 (0.94, 2.44) 1.89 (1.51, 2.54) 0.47
Data are shown as median (1st quartile, 3rd quartile), P-values are adjusted for age and baseline values. TC Total Cholesterol
Statistically significant P-values are indicated in bold
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CTT meta-analysis [29]. Clinical trials with statins and,
in general, with lipid-modifying drugs, included very
large cohorts and long-term follow-ups and enabled to
appreciate the reduction of major adverse CV events.
This important aspect has not yet been addressed by
clinical trials with nutraceuticals and remains a relevant
challenge for the future. The effects of the combination
of another probiotic (L. fermentum ME-3) with RYR and
other active components on the lipid profile has also
been recently evaluated in an open-label preliminary
study, leading to the observation of a significant − 18%
reduction of LDL-C [30]. The use of this nutraceutical
combination was associated with a slight reduction of
oxLDL levels. Interestingly, the circulating levels of
PCSK9, the main regulator of LDL-C, were not affected
by this nutraceutical combination, possibly counteract-
ing the known stimulatory effect of RYR alone on this
protein [31, 32]. Another RCT evaluating a nutraceutical
mix including RYR titrated, like in the present study, at
10 mg/day monacolin K, and the antioxidant compound
hydroxytyrosol, reported a significant − 20% reduction of
oxLDL [33].
The potential advantage of this nutraceutical combin-
ation is that it is supposed to activate two separate
mechanisms to promote LDL-C and TC reduction: in-
hibition of cholesterol synthesis in the liver by RYR ex-
tract and reduction of intestinal cholesterol absorption
by the Bifidobacterium longum BB536, through its high
BSH activity. The analysis of circulating levels of sterols
allowed to estimate the relative contribution of the two
mechanisms to the observed LDL-C and TC reduction.
As expected, a marked lathosterol:TC reduction indi-
cates a strong inhibition of cholesterol synthesis. We
found no changes of campesterol:TC and sitosterol:TC
upon active treatment. While this may be viewed as a
negative finding, it should be noted that treatment
with statins, including lovastatin, structurally identical
to monacolin K, in addition to reduce liver choles-
terol synthesis, with lathosterol:cholesterol reduction,
tends to increase intestinal cholesterol absorption,
shown by increased campesterol:cholesterol and beta-
sitosterol:cholesterol ratios [26, 34].
Although no data on specific RYR-sterols interactions
are available, since monacolin K is structurally identical
to lovastatin, one may predict that RYR extract may
behave like a statin concerning the modulation of circu-
lating sterol levels. Our findings therefore through an in-
direct mechanism suggest that Bifidobacterium longum
BB536 may effectively act to minimize a possible mona-
colin K-driven increase of cholesterol absorption, as sug-
gested by the unchanged campesterol and beta-sitosterol
levels. Future studies should assess the potential useful-
ness of probiotics like Bifidobacterium longum BB536 on
top of cholesterol synthesis inhibitors like statins. This
nutraceutical combination appears to be safe also in
terms of glucose metabolism, since no changes were
observed regarding insulin resistance and FGF19 and
FGF21 levels [35, 36].
The strengths of this study include some novel aspects
in the field of nutraceuticals for CV risk: i) the inclusion
of a probiotic with a specific biological activity (BSH) in
a nutraceutical combination, ii) the evaluation of experi-
mental markers of CV and metabolic risk, in addition to
clinical biomarkers, and iii) the assessment, for the first
time, of biomarkers of cholesterol synthesis and absorp-
tion in a RCT with nutraceuticals. A limitation of the
study is that we could not evaluate additional treatment
arms with, for example, the RYR extract or the probiotic
alone. On the other end, a nutraceutical formulation
may be advantageous (or disadvantageous) because of its
complexity and studying each single component in a
clinical trial may not be very informative.
Conclusions
A 12-week treatment with a novel nutraceutical combin-
ation containing the probiotic Bifidobacterium longum
BB536 and RYR extract was well tolerated by subjects
with low CV risk and borderline hypercholesterolemia
and resulted in a significant improvement of the
proatherogenic lipid profile. The use of nutraceuticals in
CV prevention, as well as in other areas related to
chronic diseases like oncology, is currently expanding.
Future studies may address the feasibility of “multiple
probiotic-only” or “probiotic plus prebiotic” approaches
to moderate hypercholesterolemia/CV risk.
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